Longevity research has moved from the fringes to the mainstream. A handful of scientists are doing serious work on why we age and what, if anything, can be done about it. Their approaches range from epigenetics to autophagy to clinical drug trials, and they do not all agree on the answers.
Here is a look at ten researchers worth knowing about, what they study, and where the evidence currently stands.
10 Pioneers in Longevity Research
Judith Campisi (1948–2024)
Institution: Buck Institute for Research on Aging
Focus: Cellular senescence, SASP
Campisi essentially built the scientific case for cellular senescence as a central driver of aging. Senescent cells are cells that stop dividing but refuse to die - they accumulate with age and secrete a cocktail of inflammatory signals collectively known as the SASP (Senescence-Associated Secretory Phenotype).
Her 2008 paper characterizing the SASP provided the mechanistic link between senescent cells and chronic inflammation - a major driver of age-related disease (3). She also co-founded Unity Biotechnology, which is running clinical trials of drugs designed to clear senescent cells (senolytics).
Campisi's legacy runs through most of the senolytic field that exists today. Human trials are still early, but animal studies consistently show that removing senescent cells improves physical function and lifespan.
Nir Barzilai
Institution: Albert Einstein College of Medicine
Focus: Centenarians, metformin
Barzilai has spent years studying centenarians - people who live past 100 - trying to understand what their biology has in common. His work has identified patterns in IGF-1 signaling and lipid metabolism that may confer protection against age-related disease.
He's also the lead investigator for the TAME trial (Targeting Aging with Metformin), which aims to test whether metformin - a well-established diabetes drug - can delay the onset of age-related diseases in non-diabetic older adults. TAME is notable because it's one of the first clinical trials designed to target aging itself as a primary endpoint rather than a single disease (4).
Metformin works partly by activating AMPK and suppressing mTOR - pathways involved in nutrient sensing and cellular maintenance. Whether it can extend healthspan in healthy older adults remains to be confirmed by the trial.
Ana Maria Cuervo
Institution: Albert Einstein College of Medicine
Focus: Chaperone-mediated autophagy (CMA)
Cuervo is a leading expert in CMA, a selective form of autophagy that removes damaged proteins individually. CMA declines with age, particularly in neurons, contributing to neurodegenerative disease risk (5).
Restoring CMA in animal models improves cellular resilience, though translation to human therapy remains early.
Morgan Levine
Institution: Yale (formerly), now Altos Labs
Focus: Biological age measurement
Levine's work sits at the intersection of bioinformatics and aging biology. She developed PhenoAge - an epigenetic clock that estimates a person's biological age from blood DNA methylation patterns, combined with clinical biomarkers like glucose, albumin, and C-reactive protein.
What makes PhenoAge useful is that it predicts mortality and disease risk better than chronological age alone, and it's been validated in large population datasets (6). Her lab has used these tools to measure how various interventions - like dietary changes - shift biological age in humans.
The broader promise of epigenetic clocks is that they could serve as readouts in longevity trials, giving researchers a way to measure aging rate without waiting decades for mortality endpoints.
Joan Mannick
Institution: resTORbio
Focus: mTOR inhibition, immune aging
Mannick ran some of the earliest randomized controlled trials testing whether drugs that target aging pathways can actually improve health in older humans. Her focus: mTOR - a central regulator of cell growth and metabolism.
In a 2014 trial, elderly volunteers given an mTOR inhibitor (everolimus/RAD001) for six weeks showed roughly a 20% improvement in their response to the flu vaccine - a sign of improved immune function (7). A 2018 follow-up showed that a low-dose TORC1 inhibitor combination significantly reduced infection rates in older adults over a year (8).
These are among the few published randomized trials directly targeting aging biology in humans. The effects were modest, and further trials are needed, but they establish proof of concept that rapamycin-class drugs can affect aging-related biology in people.
Related reading:
Satchidananda (Satchin) Panda
Institution: Salk Institute
Focus: Circadian rhythms, time-restricted eating
Panda's work centers on the body clock - specifically how restricting eating to a consistent 8-12 hour window each day (time-restricted eating, or TRE) can improve metabolic health, independent of what you eat.
His animal studies showed that mice eating the same number of calories in a restricted time window were protected from obesity, diabetes, and liver disease compared to mice eating freely. This effect works through the circadian regulation of mTOR, AMPK, and metabolic gene expression.
Human pilot trials of time-restricted eating have shown improvements in blood pressure, blood glucose, and inflammatory markers in various populations. However, most human studies to date are small, and the long-term effects on aging endpoints remain to be established in large clinical trials (9).
Steve Horvath
Institution: Altos Labs
Focus: Epigenetic clocks
Horvath created the original epigenetic clock - published in 2013, it used DNA methylation patterns from 353 specific sites across the genome to predict biological age from any tissue or cell type with striking accuracy. It remains one of the most cited tools in ageing research.
His clock works because methylation patterns at specific sites change predictably with age. When biological age runs faster than chronological age, a phenomenon called age acceleration - it correlates with higher disease risk and mortality.
Horvath is now at Altos Labs, a company focused on cellular reprogramming - the idea of resetting the epigenetic clock by partially activating the same genes (Yamanaka factors) that turn adult cells back into stem cells. This work is still primarily in animal models, with human application years away (10).
See also:
Cynthia Kenyon
Institution: Calico Life Sciences
Focus: IGF-1 signaling genetics
Kenyon's 1993 discovery was a landmark: a single mutation in the daf-2 gene in C. elegans worms doubled their lifespan. This gene is the worm's equivalent of the insulin/IGF-1 receptor - and it opened up the idea that aging isn't just inevitable deterioration, but a regulated biological process that can be genetically modified.
The downstream transcription factor, DAF-16 (related to FOXO proteins in mammals), turned out to be a master regulator of stress resistance, immune function, and longevity. Her work established the insulin/IGF-1 pathway as one of the most conserved aging-related pathways across species.
Kenyon is now at Calico, working on understanding aging at a molecular level. The research is mostly proprietary, but her foundational work in IGF-1 signaling continues to inform every study that looks at nutrient sensing and longevity (11).
David Sinclair
Institution: Paul F. Glenn Center for Biology of Aging Research, Harvard Medical School
Focus: Epigenetics, sirtuins, NAD⁺ metabolism
Key pathways: Sirtuins, NAD⁺, mTOR, AMPK
Sinclair's lab works on the idea that aging is primarily an epigenetic problem - not so much a buildup of genetic mutations, but a loss of how genes are read and expressed over time. He's best known for his work on sirtuins, a family of proteins that depend on NAD⁺ to regulate cellular repair and stress responses.
His lab has shown in animal models that boosting NAD⁺ levels can improve markers of metabolic health, but direct human longevity evidence is still limited. Human trials of NAD⁺ precursors are ongoing, and Sinclair co-authored a major 2024 review in Cell Metabolism summarizing the current clinical evidence for compounds targeting aging hallmarks (1).
He is also the most publicly visible scientist in the field. His bestselling book Lifespan, frequent media appearances, and openly shared personal supplement regimen have introduced millions of people to longevity science. That visibility has generated debate among peers. His early resveratrol work faced reproducibility challenges from other labs. In 2023, a dispute over epigenetic reprogramming data drew unusually public attention within the research community. Some researchers have questioned whether his public claims consistently reflect the pace of clinical evidence.
Sinclair's core contributions to sirtuin biology and epigenetic aging remain widely cited. The broader debate around his work reflects a tension the entire longevity field is navigating: how to communicate emerging science responsibly when the biology is advancing faster than clinical trials can confirm it.
Related reading:
Valter Longo
Institution: USC Longevity Institute
Focus: Dietary restriction, fasting, nutrient sensing
Key pathways: IGF-1, mTOR, autophagy
Longo has spent decades studying how what you eat - and when - affects how cells age. His lab developed the fasting-mimicking diet (FMD): a low-calorie protocol that activates many of the same cellular pathways as water fasting, without the extreme restriction.
A key mechanism is IGF-1 suppression. Lower IGF-1 signals the body to shift into a maintenance mode, activating autophagy - the cell's internal cleanup process. This has been shown to extend lifespan in yeast, worms, mice, and multiple animal models.
In humans, Longo's group published a randomized clinical trial showing that periodic FMD cycles reduced markers of metabolic disease risk, including blood glucose and inflammatory markers, in generally healthy adults (2). This is among the strongest dietary longevity trials available in humans.
See also:
The Beginning of a New Era
A generation ago, extending human lifespan was science fiction. Today, aging pathways are mapped at the molecular level, interventions targeting mTOR and metabolic signaling are moving through human trials, and biological age can be measured with increasing precision. That represents a fundamental shift. The field is no longer simply describing aging; it is designing around it. No single breakthrough will solve what is ultimately a systems problem, but layered strategies grounded in mitochondrial health, nutrient sensing, cellular repair, and epigenetic regulation are converging into something coherent. The question longevity science is asking has changed. It is no longer whether aging can be influenced. It is how precisely, how early, and how completely we can do it.
Literature Sources
- Guarente L, Sinclair DA, Kroemer G. (2024). Human trials exploring anti-aging medicines. Cell Metabolism, 40(1), 15-31. PubMed
- Wei M, Brandhorst S, Shelehchi M, et al. (2017). Fasting-mimicking diet and markers/risk factors. Sci Transl Med. PubMed
- Coppé JP, et al. (2008). The senescence-associated secretory phenotype. Annu Rev Pathol. PubMed
- Barzilai N, et al. (2016). Metformin as a tool to target aging. Cell Metabolism. PubMed
- Bourdenx M, et al. (2021). Chaperone-mediated autophagy. Cell. PubMed
- Levine ME, et al. (2018). An epigenetic biomarker of aging. Aging. PubMed
- Mannick JB, et al. (2014). mTOR inhibition improves immune function. Sci Transl Med. PubMed
- Mannick JB, et al. (2018). TORC1 inhibition enhances immune function. Sci Transl Med. PubMed
- Lowe DA, et al. (2020). Effects of time-restricted eating. JAMA Intern Med. PubMed
- Horvath S. (2013). DNA methylation age. Genome Biol. PubMed
- Kenyon C, et al. (1993). A C. elegans mutant that lives twice as long. Nature. PubMed
Image credit: Editorial composite inspired by modern longevity science.
